Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs)
Open accessThe DOI matches its Crossref record; 168 of the 168 references it cites were found in a registry or an index.
Abstract
Class I histone deacetylases (HDACs) are promising targets for epigenetic therapies for a range of diseases such as cancers, inflammations, infections and neurological diseases. Although six HDAC inhibitors are now licensed for clinical treatments, they are all pan-inhibitors with little or no HDAC isoform selectivity, exhibiting undesirable side effects. A major issue with the currently available HDAC inhibitors is that they have limited specificity and target multiple deacetylases. Except for HDAC8, Class I HDACs (1, 2 and 3) are recruited to large multiprotein complexes to function. Therefore, there are rising needs to develop new, hopefully, therapeutically efficacious HDAC inhibitors with isoform or complex selectivity. Here, upon the introduction of the structures of Class I HDACs and their complexes, we provide an up-to-date overview of the structure-based discovery of Class I HDAC inhibitors, including pan-, isoform-selective and complex-specific inhibitors, aiming to provide an insight into the discovery of additional HDAC inhibitors with greater selectivity, specificity and therapeutic utility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (A) Superposition of the structures of HDAC1–3 (PDB (Protein Data Bank) codes: 5ICN, 4LY1 and 4A69). Significant residue differences are highlighted in cyan (HDAC1 and 2) and magenta (HDAC3). Adapted with permission from Millard 2017 [15]. (B) The active site of HDAC8 (PDB code: 4QA2). Adapted with permission from Chakrabarti 2015 [17]. (C) The foot pocket of HDAC8. Prominent amino-acid side-chain differences between HDAC8 and HDAC1 in the foot pocket are shown. Adapted with permission from Whitehead 2011 [64].](https://figures.cochat.ai/paper-figures/b302b31d8cb448dbb4268c0b97574b20/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-2.jpg)
![Figure 3 Possible mechanism of catalysis by HDAC8. Adapted with permission from Porter 2019 [66].](https://figures.cochat.ai/paper-figures/30fe6dccef0d4b9c92dfc9c2bf38e523/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-3.jpg)
![Figure 4 (A) Structure of the core NuRD complex (HDAC1/RBBP4/MTA1 (162-546)). Adapted with permission from Millard 2016 [75]. (B) Substructure of the Sin3 complex. Adapted with permission from Banks 2020 [80]. (C) Structure of the CoREST complex. Adapted with permission from Song 2020 [87]. (D) Structure of the MiDAC complex in dimeric form. Adapted with permission from Turnbull 2020 [89]. (E) Structure of the SMRT/NCoR complex. Adapted with permission from Oberoi 2011 [93].](https://figures.cochat.ai/paper-figures/bf6ab3fd093741d9854ccd0d56471d17/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-4.jpg)
![Figure 5 (A) The binding site of inositol phosphate with HDAC3-SMRT complex. The inositol phosphate is shown as a stick model. Adaptedwith permission from Watson 2012 [94]. (B) Relative position of the allosteric site and binding rail on HDAC2. Adapted with permission from Zhou 2017 [96].](https://figures.cochat.ai/paper-figures/631fbed22d954b019cbe326c9840b7de/structure-based-inhibitor-discovery-of-class-i-histone-deacetylases-hdacs-figure-5.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“the development of selective inhibitors has advanced significantly.488–490”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [488]
The cited source says what the claim attributes to it.
In the citing paper
“Given the association of pan-inhibitors with cytotoxicity and adverse events”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [488]
The cited source says what the claim attributes to it.
In the citing paper
“One of the major challenges, however, in targeting HDACs 1–3 is due to their existence in multimeric states and they are often complex with other co-factors that perform different functions [6].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796 · cited 1×
“However, resveratrol is also an activator of SIRT1 with treatment potential in diverse diseases such as neurodegenerative diseases, cancers and cardiovascular diseases with distinct pharmacological mechanisms [156,157].”
BackgroundErasers of Histone Acetylation: The Histone Deacetylase Enzymes
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 1,989
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564 · cited 6×
“In neurological diseases, HDACis can induce neuroprotection and the expression of neurotrophins [8,27].”
BackgroundInfluentialNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103 · cited 1×
“Early studies have shown that HDAC1, HDAC2, RBBP4 (RbAp48) and RBBP7 (RbAp46) form the core histone deacetylase complex, which exists in both NuRD and Sin3 macromolecular complexes [71].”
BackgroundOlsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
San-Miguel, J. F., Hungria, V. T. M., Yoon, S.-S., Beksac, M., Dimopoulos, M. A., Elghandour, A., Jedrzejczak, W. W., Günther, A., Nakorn, T. N., Siritanaratkul, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70440-1 · Cited by 791
Native mass spectrometry: a bridge between interactomics and structural biology
Heck, A. J. R. (2008) · Nature Methods · doi:10.1038/nmeth.1265 · Cited by 766 · cited 1×
“In addition, XL-MS [158,159], hydrogen-deuterium exchange MS (HDX-MS) [160–162], native MS [163,164], native top–down MS [165,166] techniques have been more frequently used for the structural studies of macromolecular protein complexes [167].”
MethodPiekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710 · cited 18×
“In addition, they share a 35–160 amino acid unstructured C-terminal tail except for HDAC8, which is used to recruit protein complexes and to be post-translationally modified [15,57,62].”
BackgroundInfluentialHistone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Multiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676 · cited 1×
“Except for this, HDACs play roles in neurodegenerative diseases such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and mood disorders [11], as well as in HIV infection [12], kidney diseases [13] and inflammatory diseases [14].”
BackgroundWhittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Bantscheff, M., Hopf, C., Savitski, M. M., Dittmann, A., Grandi, P., Michon, A.-M., Schlegl, J., Abraham, Y., Becher, I., Bergamini, G., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1759 · Cited by 659
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638 · cited 6×
“In addition, they share a 35–160 amino acid unstructured C-terminal tail except for HDAC8, which is used to recruit protein complexes and to be post-translationally modified [15,57,62].”
BackgroundInfluentialRasmussen, T. A., Tolstrup, M., Brinkmann, C. R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al. (2014) · The Lancet HIV · doi:10.1016/s2352-3018(14)70014-1 · Cited by 628
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Cancer biology and NuRD: a multifaceted chromatin remodelling complex
Lai, A. Y., & Wade, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3091 · Cited by 539
Deconstructing repression: evolving models of co-repressor action
Perissi, V., Jepsen, K., Glass, C. K., & Rosenfeld, M. G. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2736 · Cited by 532 · cited 1×
“The SMRT/NCoR complex is associated with development and homeostasis in inflammation, neuronal and cardiovascular diseases [91].”
BackgroundStructure of Hdac3 Bound to Co-Repressor and Inositol Tetraphosphate
Watson, P. J., Fairall, L., Santos, G. M., & Schwabe, J. W. R. (2012) · Nature · doi:10.1038/nature10728 · Cited by 505 · cited 4×
“Crystal and NMR structures showed that SMRT interacts with HDAC3 at regions near the active site and the N-terminus of TBL1 protein forms a tetrameric interaction with SMRT and GPS2 (Figure 4E) [93,94].”
BackgroundInfluentialDelcuve, G. P., Khan, D. H., & Davie, J. R. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-5 · Cited by 505
CoREST is an integral component of the CoREST- human histone deacetylase complex
You, A., Tong, J. K., Grozinger, C. M., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1454 · Cited by 502
CoREST: A functional corepressor required for regulation of neural-specific gene expression
Andrés, M. E., Burger, C., Peral-Rubio, M. J., Battaglioli, E., Anderson, M. E., Grimes, J., Dallman, J., Ballas, N., & Mandel, G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9873 · Cited by 494
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Lauffer, B. E. L., Mintzer, R., Fong, R., Mukund, S., Tam, C., Zilberleyb, I., Flicke, B., Ritscher, A., Fedorowicz, G., Vallero, R., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.490706 · Cited by 429 · cited 2×
“Benzamide ring also provides a modifiable site target foot pockets in Class I HDACs [108].”
BackgroundMilazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
Class I HDACs Share a Common Mechanism of Regulation by Inositol Phosphates
Millard, C. J., Watson, P. J., Celardo, I., Gordiyenko, Y., Cowley, S. M., Robinson, C. V., Fairall, L., & Schwabe, J. W. R. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.05.020 · Cited by 396
HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V., Carreiro, S., Rusche, J. R., & Wood, M. A. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213364110 · Cited by 395
Lee, H.-Z., Kwitkowski, V. E., Del Valle, P. L., Ricci, M. S., Saber, H., Habtemariam, B. A., Bullock, J., Bloomquist, E., Li Shen, Y., Chen, X.-H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3119 · Cited by 357
Leitner, A., Faini, M., Stengel, F., & Aebersold, R. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.10.008 · Cited by 355
Isoform-selective histone deacetylase inhibitors
Bieliauskas, A. V., & Pflum, M. K. H. (2008) · Chemical Society Reviews · doi:10.1039/b703830p · Cited by 350
VanderMolen, K. M., McCulloch, W., Pearce, C. J., & Oberlies, N. H. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.35 · Cited by 333 · cited 1×
“Romidepsin is the only approved cyclic peptide inhibitor that is selectivity to Class I HDACs [109].”
BackgroundYang, M., Gocke, C. B., Luo, X., Borek, D., Tomchick, D. R., Machius, M., Otwinowski, Z., & Yu, H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.07.012 · Cited by 330
George, P., Bali, P., Annavarapu, S., Scuto, A., Fiskus, W., Guo, F., Sigua, C., Sondarva, G., Moscinski, L., Atadja, P., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3413 · Cited by 324
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Ning, Z.-Q., Li, Z.-B., Newman, M. J., Shan, S., Wang, X.-H., Pan, D.-S., Zhang, J., Dong, M., Du, X., & Lu, X.-P. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1766-x · Cited by 303 · cited 2×
“Chidamide (Compound 3) was approved by the Chinese National Medical Products Administration (NMPA) for the treatment of relapsed or refractory PTCL in 2014 [40,41] and breast cancer (c bined with exemestane) in 2019 [42].”
BackgroundSin3: a flexible regulator of global gene expression and genome stability
Silverstein, R. A., & Ekwall, K. (2005) · Current Genetics · doi:10.1007/s00294-004-0541-5 · Cited by 303
HDAC8: a multifaceted target for therapeutic interventions
Chakrabarti, A., Oehme, I., Witt, O., Oliveira, G., Sippl, W., Romier, C., Pierce, R. J., & Jung, M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.013 · Cited by 284 · cited 4×
“HDACs are capable of catalyzing the removal of the N-acetyl group from acetylated lysine residues in histones and non-histone proteins [17,18].”
BackgroundInfluentialStructure, mechanism, and inhibition of histone deacetylases and related metalloenzymes
Lombardi, P. M., Cole, K. E., Dowling, D. P., & Christianson, D. W. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.004 · Cited by 277
Wei, D. G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J. P., Stepan, G., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004071 · Cited by 273
Jiang, Z., Li, W., Hu, X., Zhang, Q., Sun, T., Cui, S., Wang, S., Ouyang, Q., Yin, Y., Geng, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30164-0 · Cited by 270
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Bressi, J. C., Jennings, A. J., Skene, R., Wu, Y., Melkus, R., Jong, R. D., O’Connell, S., Grimshaw, C. E., Navre, M., & Gangloff, A. R. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.091 · Cited by 261 · cited 2×
“The crystal structure revealed that the HDAC2 foot pocket consists of Tyr29, Met35, Phe114 and Leu144, and the phenyl groups of inhibitors can insert into this foot pocket [134].”
BackgroundUEDA, H., MANDA, T., MATSUMOTO, S., MUKUMOTO, S., NISHIGAKI, F., KAWAMURA, I., & SHIMOMURA, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 257
Li, H., Nguyen, H. H., Ogorzalek Loo, R. R., Campuzano, I. D. G., & Loo, J. A. (2018) · Nature Chemistry · doi:10.1038/nchem.2908 · Cited by 249 · cited 1×
“In addition, XL-MS [158,159], hydrogen-deuterium exchange MS (HDX-MS) [160–162], native MS [163,164], native top–down MS [165,166] techniques have been more frequently used for the structural studies of macromolecular protein complexes [167].”
MethodSelf-citationInsights into the activation mechanism of class I HDAC complexes by inositol phosphates
Watson, P. J., Millard, C. J., Riley, A. M., Robertson, N. S., Wright, L. C., Godage, H. Y., Cowley, S. M., Jamieson, A. G., Potter, B. V. L., & Schwabe, J. W. R. (2016) · Nature Communications · doi:10.1038/ncomms11262 · Cited by 244
Structure and function insights into the NuRD chromatin remodeling complex
Torchy, M. P., Hamiche, A., & Klaholz, B. P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1880-8 · Cited by 242
Zinc binding groups for histone deacetylase inhibitors
Zhang, L., Zhang, J., Jiang, Q., Zhang, L., & Song, W. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1417274 · Cited by 240
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Kalin, J. H., Wu, M., Gomez, A. V., Song, Y., Das, J., Hayward, D., Adejola, N., Wu, M., Panova, I., Chung, H. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02242-4 · Cited by 229
Identification of protein‐protein interactions using in vivo cross‐linking and mass spectrometry
Vasilescu, J., Guo, X., & Kast, J. (2004) · PROTEOMICS · doi:10.1002/pmic.200400856 · Cited by 226
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223
The diverse and expanding role of mass spectrometry in structural and molecular biology
Lössl, P., van de Waterbeemd, M., & Heck, A. J. (2016) · The EMBO Journal · doi:10.15252/embj.201694818 · Cited by 222
Allen, H. F., Wade, P. A., & Kutateladze, T. G. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1256-2 · Cited by 205
Integrative regulation of physiology by histone deacetylase 3
Emmett, M. J., & Lazar, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0076-0 · Cited by 202
Beckers, T., Burkhardt, C., Wieland, H., Gimmnich, P., Ciossek, T., Maier, T., & Sanders, K. (2007) · International Journal of Cancer · doi:10.1002/ijc.22751 · Cited by 192
Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
KrennHrubec, K., Marshall, B. L., Hedglin, M., Verdin, E., & Ulrich, S. M. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.02.064 · Cited by 192
Histone deacetylases: structural determinants of inhibitor selectivity
Micelli, C., & Rastelli, G. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.007 · Cited by 192
Methot, J. L., Chakravarty, P. K., Chenard, M., Close, J., Cruz, J. C., Dahlberg, W. K., Fleming, J., Hamblett, C. L., Hamill, J. E., Harrington, P., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.12.031 · Cited by 191 · cited 3×
“HDAC1/2-Selective Inhibitors Compared to HDAC8-selective inhibitors, the development of HDAC1/2/3-selective inhibitors has lagged behind owing to their high sequence similarities (85% homological identity between HDAC1 and HDAC2 and 64% between HDAC1 and HDAC3) [6,132].”
BackgroundHydrogen exchange mass spectrometry: what is it and what can it tell us?
Marcsisin, S. R., & Engen, J. R. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3556-4 · Cited by 189
Rettig, I., Koeneke, E., Trippel, F., Mueller, W. C., Burhenne, J., Kopp-Schneider, A., Fabian, J., Schober, A., Fernekorn, U., von Deimling, A., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.24 · Cited by 180
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180 · cited 8×
“More specifically, HDAC1 and HDAC2 form the catalytic core of multiple corepressor complexes, including NuRD (nucleosome remodeling and deacetylase), Sin3 (switch intensive 3) and CoREST (corepressor of RE1-silencing transcription), MiDAC (mitotic deacetylase), while HDAC3 forms the key component of SMRT/NCoR (silenci…”
BackgroundInfluentialGore, S. D., Weng, L.-J., Figg, W. D., Zhai, S., Donehower, R. C., Dover, G. H., Grever, M. R., Griffin, C. A., Grochow, L. B., Hawkins, A. L., et al. (2002) · PubMed · Cited by 169
Blumenschein, G. R., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., & Frankel, S. R. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9075-2 · Cited by 167
Suzuki, T., Ota, Y., Ri, M., Bando, M., Gotoh, A., Itoh, Y., Tsumoto, H., Tatum, P. R., Mizukami, T., Nakagawa, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300837y · Cited by 165
Structural basis for the assembly of the SMRT/NCoR core transcriptional repression machinery
Oberoi, J., Fairall, L., Watson, P. J., Yang, J.-C., Czimmerer, Z., Kampmann, T., Goult, B. T., Greenwood, J. A., Gooch, J. T., Kallenberger, B. C., et al. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1983 · Cited by 165
Whitehead, L., Dobler, M. R., Radetich, B., Zhu, Y., Atadja, P. W., Claiborne, T., Grob, J. E., McRiner, A., Pancost, M. R., Patnaik, A., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.030 · Cited by 164
Physiological Roles of Class I HDAC Complex and Histone Demethylase
Hayakawa, T., & Nakayama, J.-I. (2011) · BioMed Research International · doi:10.1155/2011/129383 · Cited by 164
Nuclear hormone receptor co-repressors: Structure and function
Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.08.033 · Cited by 162
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A
Lee, H., Rezai-Zadeh, N., & Seto, E. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.2.765-773.2004 · Cited by 153 · cited 1×
“Additionally, a unique phosphorylation on Ser39 in HDAC8 impacts protein structure and decreases the enzyme activity [69].”
BackgroundRecent Progress in Histone Deacetylase Inhibitors as Anticancer Agents
Cappellacci, L., Perinelli, D. R., Maggi, F., Grifantini, M., & Petrelli, R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666181016163110 · Cited by 147
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Zhao, C., Dong, H., Xu, Q., & Zhang, Y. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2020.1725470 · Cited by 147
Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases
Porter, N. J., & Christianson, D. W. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.01.004 · Cited by 146
Rai, M., Soragni, E., Chou, C. J., Barnes, G., Jones, S., Rusche, J. R., Gottesfeld, J. M., & Pandolfo, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008825 · Cited by 144
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 143
Wang, D.-F., Wiest, O., Helquist, P., Lan-Hargest, H.-Y., & Wiech, N. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0498497 · Cited by 141
Millard, C. J., Varma, N., Saleh, A., Morris, K., Watson, P. J., Bottrill, A. R., Fairall, L., Smith, C. J., & Schwabe, J. W. (2016) · eLife · doi:10.7554/elife.13941 · Cited by 139
Mechanism of Crosstalk between the LSD1 Demethylase and HDAC1 Deacetylase in the CoREST Complex
Song, Y., Dagil, L., Fairall, L., Robertson, N., Wu, M., Ragan, T. J., Savva, C. G., Saleh, A., Morone, N., Kunze, M. B. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.091 · Cited by 137
The application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 133
Gupta, M., Han, J. J., Stenson, M., Wellik, L., & Witzig, T. E. (2012) · Leukemia · doi:10.1038/leu.2011.340 · Cited by 132
The Search for Potent, Small‐Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat
Zagni, C., Floresta, G., Monciino, G., & Rescifina, A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21437 · Cited by 132
Novotny-Diermayr, V., Sangthongpitag, K., Hu, C. Y., Wu, X., Sausgruber, N., Yeo, P., Greicius, G., Pettersson, S., Liang, A. L., Loh, Y. K., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0689 · Cited by 131
Trabjerg, E., Nazari, Z. E., & Rand, K. D. (2018) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2018.06.008 · Cited by 125
Gupta, K. D., Shakespear, M. R., Iyer, A., Fairlie, D. P., & Sweet, M. J. (2016) · Clinical & Translational Immunology · doi:10.1038/cti.2015.46 · Cited by 124
Marek, M., Shaik, T. B., Heimburg, T., Chakrabarti, A., Lancelot, J., Ramos-Morales, E., Da Veiga, C., Kalinin, D., Melesina, J., Robaa, D., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01087 · Cited by 122 · cited 1×
“revealed that the binding mode of PCI-34051 and NCC-149 with Schistosoma mansoni HDAC8 (smHDAC8) through X-ray crystallization [120].”
BackgroundHistone deacetylase 3 (HDAC3) inhibitors as anticancer agents: A review
Sarkar, R., Banerjee, S., Amin, S. A., Adhikari, N., & Jha, T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112171 · Cited by 121
Johnson, C. A., White, D. A., Lavender, J. S., O'Neill, L. P., & Turner, B. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107942200 · Cited by 119 · cited 1×
“HDACs are capable of catalyzing the removal of the N-acetyl group from acetylated lysine residues in histones and non-histone proteins [17,18].”
BackgroundCrystal Structure of the LSD1/CoREST Histone Demethylase Bound to Its Nucleosome Substrate
Kim, S.-A., Zhu, J., Yennawar, N. H., Eek, P., & Tan, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.019 · Cited by 119
Su, J. M. F., Li, X., Thompson, P., Ou, C., Ingle, A. M., Russell, H. V., Lau, C. C., Adamson, P. C., & Blaney, S. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0738 · Cited by 113
Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview
Banerjee, S., Adhikari, N., Amin, S. A., & Jha, T. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.039 · Cited by 108
Hydrogen/deuterium exchange in mass spectrometry
Kostyukevich, Y., Acter, T., Zherebker, A., Ahmed, A., Kim, S., & Николаев, Е. Н. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21565 · Cited by 108
Turnbull, R. E., Fairall, L., Saleh, A., Kelsall, E., Morris, K. L., Ragan, T. J., Savva, C. G., Chandru, A., Millard, C. J., Makarova, O. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17078-8 · Cited by 108
Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives
Hailu, G. S., Robaa, D., Forgione, M., Sippl, W., Rotili, D., & Mai, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01595 · Cited by 103
Ononye, S. N., VanHeyst, M. D., Oblak, E. Z., Zhou, W., Ammar, M., Anderson, A. C., & Wright, D. L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400158k · Cited by 102
Suzuki, T., Kasuya, Y., Itoh, Y., Ota, Y., Zhan, P., Asamitsu, K., Nakagawa, H., Okamoto, T., & Miyata, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068669 · Cited by 101
Discovery of histone deacetylase 8 selective inhibitors
Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 98
Qiu, X., Xiao, X., Li, N., & Li, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.002 · Cited by 96
McClure, J. J., Zhang, C., Inks, E. S., Peterson, Y. K., Li, J., & Chou, C. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01385 · Cited by 96
Wang, Z., Chen, Z., Jiang, G., Wu, Y., Liu, T., Yi, Y., Zeng, J., Du, J., & Wang, H. (2016) · Cellular Signalling · doi:10.1016/j.cellsig.2016.02.006 · Cited by 90
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 89
Wagner, F. F., Lundh, M., Kaya, T., McCarren, P., Zhang, Y.-L., Chattopadhyay, S., Gale, J. P., Galbo, T., Fisher, S. L., Meier, B. C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b00640 · Cited by 86 · cited 2×
“A docking study indicated that the selectivity originates from the conformational differences of Try107 and Leu144 [139].”
BackgroundHuang, W., Wang, Y., Chao, S.-W., Yang, C., Chen, L., Lin, M., Hou, W., Chen, M., Lee, T., Yang, P., et al. (2012) · ChemMedChem · doi:10.1002/cmdc.201200300 · Cited by 85
p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102415 · Cited by 85
Cao, L., Song, X., Pei, L., Liu, L., Wang, H., & Jia, M. (2017) · Medicine · doi:10.1097/md.0000000000007663 · Cited by 85
Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0980-t · Cited by 83
On the inhibition of histone deacetylase 8
Estiu, G., West, N., Mazitschek, R., Greenberg, E., Bradner, J. E., & Wiest, O. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.080 · Cited by 82
Entinostat for the treatment of breast cancer
Trapani, D., Esposito, A., Criscitiello, C., Mazzarella, L., Locatelli, M., Minchella, I., Minucci, S., & Curigliano, G. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1353077 · Cited by 80
Wagner, F. F., Weïwer, M., Steinbacher, S., Schomburg, A., Reinemer, P., Gale, J. P., Campbell, A. J., Fisher, S. L., Zhao, W., Reis, S. A., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.06.040 · Cited by 79
Rodrigues, D. A., Pinheiro, P. D. S. M., Sagrillo, F. S., Bolognesi, M. L., & Fraga, C. A. M. (2020) · Medicinal Research Reviews · doi:10.1002/med.21701 · Cited by 79
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018027409 · Cited by 78
Li, H., Wongkongkathep, P., Van Orden, S. L., Ogorzalek Loo, R. R., & Loo, J. A. (2014) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-014-0928-6 · Cited by 75
Self-citationChidamide in the treatment of peripheral T-cell lymphoma
Chan, T. S. Y., Tse, E., & Kwong, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s93528 · Cited by 75
Targeting triple negative breast cancer with histone deacetylase inhibitors
Fedele, P., Orlando, L., & Cinieri, S. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1386172 · Cited by 75
Suzuki, T., Muto, N., Bando, M., Itoh, Y., Masaki, A., Ri, M., Ota, Y., Nakagawa, H., Iida, S., Shirahige, K., et al. (2014) · ChemMedChem · doi:10.1002/cmdc.201300414 · Cited by 71
Halder, A. K., Mallick, S., Shikha, D., Saha, A., Saha, K. D., & Jha, T. (2015) · RSC Advances · doi:10.1039/c5ra12606a · Cited by 71
Farias, E. F., Petrie, K., Leibovitch, B., Murtagh, J., Chornet, M. B., Schenk, T., Zelent, A., & Waxman, S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006737107 · Cited by 68
Targeting breast cancer stem cells by novel HDAC3-selective inhibitors
Hsieh, H.-Y., Chuang, H.-C., Shen, F.-H., Detroja, K., Hsin, L.-W., & Chen, C.-S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.069 · Cited by 67
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66
Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
Gong, P., Wang, Y., & Jing, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071601 · Cited by 66
Li, H., Sheng, Y., McGee, W. M., Cammarata, M. B., Holden, D. D., & Loo, J. A. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02377 · Cited by 63
Self-citationTherapeutic effects of histone deacetylase inhibitors on heart disease
Chun, P. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01297-0 · Cited by 63
Itoh, T., Fairall, L., Muskett, F. W., Milano, C. P., Watson, P. J., Arnaudo, N., Saleh, A., Millard, C. J., El-Mezgueldi, M., Martino, F., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv068 · Cited by 61
Azetidinones as Zinc‐Binding Groups to Design Selective HDAC8 Inhibitors
Galletti, P., Quintavalla, A., Ventrici, C., Giannini, G., Cabri, W., Penco, S., Gallo, G., Vincenti, S., & Giacomini, D. (2009) · ChemMedChem · doi:10.1002/cmdc.200900309 · Cited by 61
Emerging Roles of Epigenetic Regulator Sin3 in Cancer
Bansal, N., David, G., Farias, E., & Waxman, S. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.01.006 · Cited by 61
Zhijun, H., Shusheng, W., Min, H., Jianping, L., Li-Sen, Q., & Li, D. (2016) · Tumor Biology · doi:10.1007/s13277-016-4868-6 · Cited by 60
Becher, I., Dittmann, A., Savitski, M. M., Hopf, C., Drewes, G., & Bantscheff, M. (2014) · ACS Chemical Biology · doi:10.1021/cb500235n · Cited by 60 · cited 2×
“Using a chemoproteomics method combined affinity capture and quantitative mass spectrometry, Bantscheff and oworkers de onstrated that benzamides hibitors can h ve different affinities to distinct HDAC complexes [147,148].”
MethodTabackman, A. A., Frankson, R., Marsan, E. S., Perry, K., & Cole, K. E. (2016) · Journal of Structural Biology · doi:10.1016/j.jsb.2016.06.023 · Cited by 60
Leighton, G. O., & Williams, D. C. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.10.007 · Cited by 59
Weerasinghe, S. V. W., Estiu, G., Wiest, O., & Pflum, M. K. H. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800081j · Cited by 58
von Tresckow, B., Sayehli, C. M., Aulitzky, W. E., Goebeler, M.-E., Schwab, M. G., Braz, E., Krauss, B., Krauss, R., Hermann, F., Bartz, R., et al. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13188 · Cited by 57
Zinc-Containing Metalloenzymes: Inhibition by Metal-Based Anticancer Agents
Ye, R., Tan, C., Chen, B.-C., Li, R., & Mao, Z. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00402 · Cited by 57
Marson, C. M., Matthews, C. J., Yiannaki, E., Atkinson, S. J., Soden, P. E., Shukla, L., Lamadema, N., & Thomas, N. S. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400634n · Cited by 54
Targeting HDAC Complexes in Asthma and COPD
Zwinderman, M. R. H., de Weerd, S., & Dekker, F. J. (2019) · Epigenomes · doi:10.3390/epigenomes3030019 · Cited by 52
Tilekar, K. N., Upadhyay, N., Jänsch, N., Schweipert, M., Mrówka, P., Meyer‐Almes, F., & Ramaa, C. S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103522 · Cited by 52
Therapeutic effects of histone deacetylase inhibitors on kidney disease
Chun, P. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0998-7 · Cited by 52
Chen, Y., He, R., Chen, Y., D'Annibale, M. A., Langley, B., & Kozikowski, A. P. (2009) · ChemMedChem · doi:10.1002/cmdc.200800461 · Cited by 51
Fuller, N. O., Pirone, A., Lynch, B. A., Hewitt, M. C., Quinton, M. S., McKee, T. D., & Ivarsson, M. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00620 · Cited by 51
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53
Mrakovcic, M., Bohner, L. O. L., Hanisch, M. R., & Fröhlich, L. F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123952 · Cited by 51
Integrative Modeling of a Sin3/HDAC Complex Sub-structure
Banks, C. A. S., Zhang, Y., Miah, S., Hao, Y., Adams, M. K., Wen, Z., Thornton, J. L., Florens, L. A., & Washburn, M. P. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.03.080 · Cited by 50
Sixto‐López, Y., Bello, M., & Correa‐Basurto, J. (2018) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2018.1441072 · Cited by 49
Trivedi, P., Adhikari, N., Amin, S. A., Bobde, Y., Routholla, G., Jha, T., & Ghosh, B. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105046 · Cited by 47
Computational Design of a Time-Dependent Histone Deacetylase 2 Selective Inhibitor
Zhou, J., Li, M., Chen, N., Wang, S., Luo, H.-B., Zhang, Y., & Wu, R. (2015) · ACS Chemical Biology · doi:10.1021/cb500767c · Cited by 45
Histone deacetylase inhibitor based prodrugs
Fan, W., Zhang, L., Jiang, Q., Song, W., Yan, F., & Zhang, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112628 · Cited by 45
Taha, T. Y., Aboukhatwa, S. M., Knopp, R. C., Ikegaki, N., Abdelkarim, H., Jayaprakash, N., Lu, Y., Neelarapu, R., Hanigan, T. W., Thatcher, G. R. J., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00126 · Cited by 44
Uba, A. İ., & Yelekçi, K. (2017) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2017.1384402 · Cited by 43
Noh, H., & Seo, H. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.012 · Cited by 41
A distal regulatory region of a class I human histone deacetylase
Werbeck, N. D., Shukla, V. K., Kunze, M. B. A., Yalinca, H., Pritchard, R. B., Siemons, L., Mondal, S., Greenwood, S. O. R., Kirkpatrick, J., Marson, C. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17610-w · Cited by 40 · cited 1×
“Recently, an NMR study revealed that Helix1-Loop1-Helix2 is an allosteric site of HDAC8 [98].”
BackgroundMetal-dependent Deacetylases: Cancer and Epigenetic Regulators
López, J. E., Sullivan, E. D., & Fierke, C. A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01067 · Cited by 37
Ravichandiran, P., Jegan, A., Dhanaraj, P., Periasamy, V. S., Muthusubramanian, S., & Vasanthkumar, S. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.01.002 · Cited by 36
Mondal, B., Jin, H., Kallappagoudar, S., Sedkov, Y., Martinez, T., Sentmanat, M. F., Poet, G. J., Li, C., Fan, Y., Pruett-Miller, S. M., et al. (2020) · eLife · doi:10.7554/elife.57519 · Cited by 35
Bansal, N., Petrie, K. R., Christova, R., Chung, C., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E. J., Wexler, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6048 · Cited by 34
Reddy, S. A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.07.001 · Cited by 34
Selective and Nonselective HDAC8 Inhibitors: a Therapeutic Patent Review
Adhikari, N., Amin, S. A., & Jha, T. (2018) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2018-0019 · Cited by 32
Liu, J., Kelly, J., Yu, W., Clausen, D., Yu, Y., Kim, H., Duffy, J. L., Chung, C. C., Myers, R. W., Carroll, S., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00302 · Cited by 32 · cited 2×
“Additionally, it as been reported that selectively inhibiting HDAC3 may help to discover some antiath sclerotic drugs [28,56].”
BackgroundBanks, C. A. S., Thornton, J. L., Kempf, C. G., Adams, M. K., Miah, S., Boanca, G., Liu, X., Katt, M. L., Parmely, T. J., Florens, L. A., et al. (2018) · Molecular & Cellular Proteomics · doi:10.1074/mcp.tir118.000661 · Cited by 30
Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Zhan, P., Wang, X., Liu, X., & Suzuki, T. (2017) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892811666161101102842 · Cited by 25
Saravanan, K., Subramani, P., Srinivasan, K., Jayaraj, J. M., Gunasekaran, P., Muthusamy, K., Venkatachalam Rajakannan, B., & Ravikumar, V. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.128177 · Cited by 21
Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L. H. M., Chung, C., Ariztia, E. V., Zelent, A., Farias, E., & Waxman, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11381 · Cited by 19
Inhibition mechanism of SAHA in HDAC: a revisit
Zhou, J., Wu, R., & Luo, H. (2015) · Physical Chemistry Chemical Physics · doi:10.1039/c5cp05633k · Cited by 18
Yu, X., Yang, F., Jiang, H., & Fan, L. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s234871 · Cited by 18
Greenwood, S. O. R., Chan, A. W. E., Hansen, D. F., & Marson, C. M. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126926 · Cited by 16
Zhang, M., Ying, J. B., Wang, S., He, D., Zhu, H., Zhang, C., Tang, L., Lin, R., & Zhang, Y. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29583 · Cited by 15
Intrinsic Dynamics of the Binding Rail and Its Allosteric Effect in the Class I Histone Deacetylases
Zhou, J., Huang, Y., Cheng, C., Wang, K., & Wu, R. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00251 · Cited by 13
Leng, K. W., Castañeda, C. A., Decroos, C., Islam, B., Haider, S. M., Christianson, D. W., & Fierke, C. A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00653 · Cited by 12
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Advances in targeting histone deacetylase for treatment of solid tumors
Shi, M.-Q., Xu, Y., Fu, X., Pan, D.-S., Lu, X.-P., Xiao, Y., & Jiang, Y.-Z. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01551-8 · Cited by 161
Shetty, M. G., Pai, P., Deaver, R. E., Satyamoorthy, K., & Babitha, K. S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105695 · Cited by 78
Histone deacetylases and their inhibitors in inflammatory diseases
Zhang, S.-Y., Zhang, L., Wen, R., Yang, N., & Zhang, T. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117295 · Cited by 89
Metadata
- Authors
- Luo, Y., & Li, H.
- Affiliations
- Sun Yat-sen University (CN)
- Corresponding author
- Li, Huilin
- ORCID
- Li, Huilin
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-22
- Volume
- 21
- Issue
- 22
- Pages
- 8828
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7700698
- OpenAlex
- W3108284227
- Cited by
- 62
- References
- 168
- Citations by year
- 2026: 15 · 2025: 12 · 2024: 11 · 2023: 11 · 2022: 5 · 2021: 8
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (91953102)
- Guangdong Nature Science Foundation (2019A1515011265)
- Fundamental Research Funds for the Sun Yat-sen Universities (19ykzd26)
- the Pearl River Talent Recruitment Program (2019QN01Y299)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Keywords
- class I histone deacetylases, histone deacetylase inhibitors, structure-based drug design, isoform selectivity, epigenetic therapy, HDAC8, protein complexes, inhibitor specificity
- MeSH terms
- Animals, Histone Deacetylases, Humans, Protein Conformation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.